Metrikler
Yayın
19
Açık Erişim
3
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (17)
SCI-E, SSCI, AHCI (15)
SCI-E, SSCI, AHCI, ESCI (15)
Scopus (15)
TRDizin (4)
Diğer Yayınlar (1)
2026
20261. Emerging Survival Predictor Model in Essential Thrombocythemia: The AAA+ Model
Sönmez Ö., Oyur E., Yönal Hindilerden İ., Hindilerden F., SÖNMEZ M., Karışmaz A., et al.
American Journal of Hematology
, cilt.101, sa.4, ss.880-883, 2026 (SCI-Expanded, Scopus)
2026
20262. A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond
Sönmez Ö., Oyur E., Yönal Hindilerden İ., Hindilerden F., SÖNMEZ M., Karışmaz A., et al.
Blood Advances
, cilt.10, sa.4, ss.1250-1259, 2026 (SCI-Expanded, Scopus)
2025
20253. The role of CD40L-expressing CXCR5+CD8+ follicular cytotoxic T cells in chronic lymphocytic leukemia
Akboga F., Hindilerden F., Hindilerden I. Y., Gulturk E., DENİZ G., GELMEZ M. Y.
Immunologic Research
, cilt.73, sa.1, 2025 (SCI-Expanded, Scopus)
2025
20254. Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology
Baysal M., Aksoy E., Bedir K. H., ÖZMEN İBİŞ D., Patır P., Demirci U., et al.
Journal of Thrombosis and Thrombolysis
, cilt.58, sa.2, ss.284-298, 2025 (SCI-Expanded, Scopus)
2023
20235. Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers
Sadri S., Yonal-Hindilerden I., mutlu Y. g., tiryaki t. o., Gemici A., Beköz H. S., et al.
The European Research Journal
, cilt.9, sa.6, ss.1368-1379, 2023 (TRDizin)
2023
20236. Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores İleri Yaştaki İmmün Trombotik Trombositopenik Purpura Hastalarında; PLASMIC ve French Skorlamalarının Rolü
Baysal M., Hindilerden F., ÜMİT E. G., DEMİR A. M., Karadağ F. K., Saydam G., et al.
Turkish Journal of Hematology
, cilt.40, sa.4, ss.251-257, 2023 (SCI-Expanded)
2022
20227. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
Akpinar S., Dogu M. H., ÇELİK S., Ekinci O., Hindilerden I. Y., Dal M. S., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, cilt.22, sa.3, ss.169-173, 2022 (SCI-Expanded)
2022
20228. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
Ulu B. U., Dal M. S., Hindilerden I. Y., Akay O. M., MEHTAP Ö., Buyukkurt N., et al.
JOURNAL OF CHEMOTHERAPY
, cilt.34, sa.3, ss.190-198, 2022 (SCI-Expanded, Scopus)
2022
20229. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
CİVRİZ BOZDAĞ S., CENGİZ SEVAL G., Hindilerden I. Y., Hindilerden F., ANDIÇ N., BAYDAR M., et al.
TURKISH JOURNAL OF HEMATOLOGY
, cilt.39, sa.1, ss.43-54, 2022 (SCI-Expanded, Scopus, TRDizin)
2021
202110. Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma
Yonal-Hindilerden I., Hindilerden F., Mastanzade M., Tiryaki T. O., Tasan-Yenigun S., BİLEN Y., et al.
FRONTIERS IN ONCOLOGY
, cilt.11, 2021 (SCI-Expanded, Scopus)
2021
202111. Rapid progression after ibrutinib discontinuation in a patient with mantle cell lymphoma who has severe coronavirus disease 2019 infection
Hindilerden F., Hindilerden I. Y., Kucukkaya R. D.
BALKAN MEDICAL JOURNAL
, cilt.38, sa.2, ss.141-142, 2021 (SCI-Expanded)
2020
202012. Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case
Hindilerden F., Yonal-Hindilerden I., Akar E., Kart-Yasar K.
THROMBOSIS RESEARCH
, cilt.195, ss.136-138, 2020 (SCI-Expanded, Scopus)
2020
202013. The Clinical Significance of JAK2V617F Mutational Status on Phenotypic Features in Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Sahin E., Yonal-Hindilerden I., Hindilerden F., Daglar-Aday A., Nalcaci M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, cilt.20, 2020 (SCI-Expanded, Scopus)
2020
202014. The Clinical Impact of the Burden of JAK2V617F Mutated Allele in Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Yonal-Hindilerden I., Sahin E., Hindilerden F., Daglar-Aday A., Nalcaci M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
, cilt.20, 2020 (SCI-Expanded, Scopus)
2020
202015. Immune Thrombocytopenia in a Very Elderly Patient With Covid-19
Hindilerden F., Yonal-Hindilerden I., Sevtap S., Kart-Yasar K.
FRONTIERS IN MEDICINE
, cilt.7, 2020 (SCI-Expanded, Scopus)
2020
202016. Severe Autoimmune Hemolytic Anemia in COVID-19 Infection, Safely Treated with Steroids
Hindilerden F., Yonal-Hindilerden I., Akar E., Yesilbag Z., Kart-Yasar K.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
, cilt.12, 2020 (SCI-Expanded, Scopus)
2016
201617. The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis.
YONAL-HINDILERDEN I., Daglar-Aday A., HINDILERDEN F., AKADAM-TEKER B., YILMAZ C., NALCACI M., et al.
Journal of clinical medicine research
, cilt.8, ss.29-39, 2016 (Hakemli Dergi)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2025
20251. A practical tool for predicting outcomes in essential thrombocythemia: Triple (or quadruple) a risk model
Sonmez O., Oyur E., Hindilerden I. Y., Hindilerden F., SÖNMEZ M., Karismaz A., et al.
67th Annual Meeting of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 6 - 09 Aralık 2025, cilt.146, ss.3805-3806, (Özet Bildiri)
2010
20102. Outcome of mycophenolate mophetil treatment in patients with proliferative lupus nephritis.
ARTIM ESEN B., ÖZLÜK M. Y., KILIÇASLAN I., HİNDİLERDEN F., KAMALI S., GÜL A., et al.
The 19th International Congress on SLE, Vancouver, Kanada, 24 - 27 Haziran 2010, ss.169, (Tam Metin Bildiri)